WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Bristol-Myers Squibb

Bristol-Myers SquibbBristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

www.bms.com.

Bristol-Myers Squibb RSS Channel

Filters
List of articles in category Bristol-Myers Squibb
Title Published Date
Bristol-Myers Squibb and Ambrx Announce Collaboration 22 September 2011
Bristol-Myers Squibb and Ono Enter into Strategic Agreement 21 September 2011
Bristol-Myers Squibb Completes Acquisition of Amira Pharmaceuticals 09 September 2011
Bristol-Myers Squibb Delivers Excellent Second Quarter 05 August 2011
Bristol-Myers Squibb to Acquire Amira Pharmaceuticals 22 July 2011
FDA Advisory Committee Makes Recommendation on Investigational Compound Dapagliflozin 21 July 2011
Bristol-Myers Squibb and Innate Pharma Announce Breakthrough Global License Agreement 07 July 2011
Bristol-Myers Squibb to Expand Access to Reyataz® in sub-Saharan Africa and India 29 June 2011
Bristol-Myers Squibb Foundation Awards $1.5 Million in Grants 27 June 2011
Bristol-Myers Squibb and Roche Enter into a Clinical Collaboration Agreement 03 June 2011
Bristol-Myers Squibb Delivers Excellent First Quarter with YERVOY™ (ipilimumab) Approval 29 April 2011
Phase III Study of Investigational Compound Ipilimumab Achieves Primary Endpoint 22 March 2011
Bristol-Myers Squibb Delivers Solid Fourth Quarter Results 27 January 2011
Pediatric Exclusivity For PLAVIX® 25 January 2011
People to Actively Manage Their Type 2 Diabetes 11 January 2011
KOMBIGLYZE™ XR Now Available in U.S. Pharmacies 09 January 2011
Bristol-Myers Squibb and Oncolys BioPharma Enter Global Licensing Agreement 21 December 2010
Encouraging Phase 2 Interim Data for Elotuzumab in Relapsed Multiple Myeloma 07 December 2010
Bristol-Myers Squibb and Alvin Ailey American Dance Theater Announce First-of-Its-Kind Collaboration 01 December 2010
APPRAISE-2 Study with Investigational Compound Apixaban Discontinued 21 November 2010
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End

Business & Industry

  • Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
  • BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
  • Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma
  • AstraZeneca launches call for entries to the 2023 global R&D Postdoctoral Challenge
  • Pfizer invests $43 billion to battle cancer

Research & Development

  • 'Biohybrid' device could restore function in paralysed limbs
  • Scientists use tardigrade proteins for human health breakthrough
  • DNA treatment could delay paralysis that strikes nearly all patients with ALS
  • Scientists reveal a potential new approach to treating liver cancer
  • Normalizing tumor blood vessels may improve immunotherapy against brain cancer
  • Engineered bacteria find tumors, then alert the authorities
  • First nasal monoclonal antibody treatment for COVID-19 shows promise for treating virus, other diseases

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  • FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
  1. You are here:  
  2. Home
  3. Bristol-Myers Squibb

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.